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Abstract
Purpose: Platinum-refractory or relapsed squamous cell carcinoma of the head and neck (SCCHN) is considered to 
have poor prognosis. Although cetuximab is currently recommended as category 1 in this group of patients, the use of it 
is hampered in low- and middle-income countries (LMICs) like Pakistan due to financial constraints. Further, majority 
of the population of these countries is unable to tolerate toxicity related to other intravenous chemotherapeutic agents 
due to lower socioeconomic background with poor nutrition status. The aim of this study is to evaluate the response 
rate and toxicity of oral methotrexate (MTX) in platinum-refractory or relapsed SCCHN.
Methods: Between June 2008 and December 2012, 71 patients received palliative oral MTX either due to recurrent 
or persistent disease. With a median age of 51 years (range 22–75), there were 68% of males and 32% of females. Site 
distribution was as following; oral cavity 58%, nasopharynx 25%, hypopharynx 7%, paranasal sinuses 6%, larynx 3%, 
Oropharynx 1%. Patterns of recurrence; local 32%, regional 07%, loco-regional 10%, distant 15% and persistent disease 
in 36% of the patients. All the patients received oral MTX 10 mg once a day, 4 days a week. To contain the possible side 
effects associated with MTX, folinic acid 15 mg per oral every 6 hourly on day 5 was prescribed. Response assessment 
was done on two monthly basis. Response, toxicity, mean response time and mean time to progression were determined.
Results: Response to MTX was as following; complete response 3%, partial response 4%, stable disease 11% and 
progressive disease in 82% of the patients respectively. Toxicity related to oral MTX includes neutropenia Grade III 
in 1% while mucositis Grade III in 10% of the patients, respectively. None of the patient had Grade IV mucositis or 
haematological toxicity. Treatment was stopped in 13% of the patients due to poor compliance. Mean response time 
was 4 months (range 1 – 20) and mean time to progression was 5 months (range 1–23).
Conclusion: Oral MTX is a simple, cost-effective and well-tolerated regimen to be used on outpatient basis for 
palliation in platinum-refractory or relapsed SCCHN in LMICs and debilitated patients. This treatment merits further 
evaluation in large-scale clinical trials.
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Introduction
Squamous cell carcinoma of the head and neck (SCCHN) 
is the sixth most common cancer in the world, with 
approximately half million new cases per year.[1] Two-
thirds of patients present with locally advanced disease and 
10% are metastatic.[2] Despite the progress in the primary 
treatment by combining chemotherapy, surgery, radiation 
therapy and supportive care, 30–50% of the patients 
eventually develop locoregional or distant relapse.[3]
Patients with recurrent or metastatic SCCHN have poor 
prognosis as they have limited treatment options.[4,5] A 
few patients with locoregional recurrence can be salvaged 
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by surgery or reirradiation. Palliative chemotherapy is 
considered as standard of care in these patients. Platinum-
based regimen with 5-FU is often considered as standard 
in patients with good performance status.[4,6,7] The other 
drugs that have been used are methotrexate (MTX), 
bleomycin, capecitabine and ifosfamide.[8] These drugs 
produce response rate up to 30% while introduction of 
new chemotherapy agents such as taxane can increase 
response rate up to 43%.[9] However, none of these drugs 
as single agent or in combination have been found to 
prolong survival.[10]
The use of cetuximab in combination with cisplatin and 
5 FU leads to an improvement in overall survival (OS) 
with respect to cisplatin and 5FU combination. That is 
why ESMO and NCCN recommend it as category 1 in 
recurrent and/or metastatic (R/M) SCCHN.[3,7,11-13]
Options are further limited for the patients who fail 
after platinum-based chemotherapy, and response rates 
are generally poor (approximately 3%).[9] Leon et al.[14] 
investigated the best supportive care for patients with 
platinum-refractory SCCHN and showed a median 
survival time of 56 days. Herbst et al.[15] reported that 
median OS was 4.3 months and response rate was 13% 
in platinum-refractory patients treated with cetuximab 
and cisplatin regimen. Cetuximab is currently considered 
to be standard of care for this population of patients. 
However, the utilization of this agent in our country is 
hampered by the financial and logistic considerations. 
Other options are taxanes, MTX, bleomycin, capecitabine 
and ifosfamide.[8,9]
In low- and middle-income countries (LMICs) like 
Pakistan, where head and neck cancer is prevalent 
in people with low socioeconomic status, the use of 
cetuximab is not feasible due to financial constraints. 
Further, majority of the population of these countries 
with SCCHN is unable to tolerate toxicity related to 
other intravenous chemotherapeutic agents due to lower 
socioeconomic background with poor nutrition status. 
MTX, most economical and least toxic, is a very good 
alternative for this selected group of patients.
In this retrospective study, we investigated the efficacy 
and tolerability of oral MTX in platinum-refractory or 
relapsed SCCHN patients. Oral MTX was given due to 
the reason that patients were not willing for intravenous 
MTX or not able to come to hospital on weekly basis from 
remote areas of the country.
Methods
Clinical data were obtained retrospectively from hospital 
information system. Patients meeting the following 
criteria were enrolled: (i) Histologically confirmed 
SCCHN, (ii) previous cisplatin-based chemotherapy 
either as definitive chemoradiotherapy or induction 
chemotherapy or post-operative chemoradiotherapy 
and (iii) documented R/M disease after platinum-based 
chemotherapy given as part of initial treatment. For this 
study, appropriate approvals were obtained from the 
institutional review committee.
These patients received oral MTX 10 mg once a day, 4 days 
a week. To contain the possible side effects associated with 
MTX, folinic acid 15 mg per oral every 6 hourly on day 
5 was prescribed. MTX was continued till progression of 
disease. After progression, few (2%) of the patients were 
irradiated. Pre-treatment evaluation included medical 
history, physical examination, laboratory tests, computed 
tomography (CT) and/or magnetic resonance imaging 
(MRI) system. Response assessment was done on two 
monthly basis. Response was evaluated by CT or MRI 
according to the Response Evaluation Criteria in Solid 
Tumours version 1.0 or clinically. Response was categorised 
as complete response (CR), partial response (PR), stable 
disease (SD) or progressive disease (PD) in this study. 
Adverse events were evaluated according to the National 
Cancer Institute Common Toxicity Criteria version 3.0.
Progression-free survival (PFS) was calculated from the 
date of the first administration of oral MTX to the earliest 
date when the treatment was discontinued for PD. If the 
treatment was discontinued due to reasons other than PD, 
PFS was calculated from the date of the first administration 
of oral MTX to the date when the disease worsened or 
when the patient died from any cause. OS time was 
calculated from the date of the first administration of oral 
MTX to the date of death from any cause or to the last 
date of confirmed survival. Survivals were analysed by 
the Kaplan–Meier method.
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Results
Between June 2008 and December 2012, a total of 
71 patients with R/M SCCHN were treated with oral 
MTX according to the above treatment schedule at 
Shaukat Khanum Memorial Cancer Hospital and 
Research Centre, Lahore, Pakistan. All the patients 
had very low socioeconomic status and ECOG PS 1–3. 
With a median age of 51 years (range 22–75), there 
were 73% of males and 27% of females. All the patients 
were previously given cisplatin-based chemotherapy 
either as definitive chemoradiotherapy or induction 
chemotherapy or post-operative chemoradiotherapy. Site 
distribution was as oral cavity 58%, nasopharynx 25%, 
hypopharynx 7%, paranasal sinuses 6%, larynx 3% and 
oropharynx 1%. Patterns of recurrence were as follows: 
Local 32%, regional 7%, locoregional 10%, distant 15% 
and persistent disease in 36% of the patients. 89% of 
the patients had T3-T4 disease and 74% of the patients 
had node-positive disease at the time of presentation. 
Table 1 summarises the patient characteristics. Initial 
treatment schedule was as follows: 7 (10%) patients 
were treated with definitive chemoradiotherapy, 
57 (80%) with induction chemotherapy followed by 
chemoradiotherapy, 3 (4%) with induction chemotherapy 
followed by surgery and radiotherapy and 4 patients (6%) 
with induction chemotherapy followed by surgery and 
chemoradiotherapy.
The toxicity noted was minimal. None of the patient had 
Grade 4 mucositis or haematological toxicity. 64 patients 
(90%) had Grade 0, 1 or 2 while 7 (10%) patients had 
Grade 3 mucositis. In haematological toxicity, only one 
patient had Grade 3 neutropenia while 11% of patients 
had Grades 1 or 2 neutropenia. It is very notable that most 
of the patients (88%) had no haematological toxicity at 
all. The details of other toxicities are shown in Table 2.
The response rates at the end of 2 months are depicted in 
Table 3. The most common cause of discontinuation of 
chemotherapy was progression of disease (49 patients [69%]) 
and intolerable side effects in 5 (7%). Symptom control was 
seen 55 (77%) patients. The median follow-up was 5 months. 
The crude median PFS was 5 months. The Kaplan–Meir 
graph for estimated PFS is depicted in Figure 1.
In this study, we used oral MTX (10 mg once a day, 4 
days a week) and it appeared to have promising signs of 
efficacy and an acceptable safety profile for the treatment 
of platinum-refractory or relapsed SCCHN patients. 
Very few of the platinum-refractory or relapsed SCCHN 
patients are suitable for salvage surgery or reirradiation. 
Most of them qualify for palliative chemotherapy. In these 
patients, therapeutic options are modest, and the duration 
of response and survival are usually short. Attempts have 
made to improve survival of these patients with different 
chemotherapy agents such as taxanes (docetaxel and 
Table 1: Patient characteristics
Patient characteristics n (%)





Oral cavity 41 (58)
Nasopharynx 18 (25)
Hypopharynx 05 (07)





















*CRT: Definitive chemoradiotherapy, †C+CRT: Induction chemother‑
apy followed by chemoradiotherapy, ‡C+S+RT: Induction chemo‑
therapy followed by surgery and radiotherapy, §C+S+CRT: Induction 
chemotherapy followed by surgery and chemoradiotherapy
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paclitaxel), MTX, bleomycin, capecitabine, ifosfamide, 
vinorelbine, irinotecan, S-1 and cetuximab. However, 
none of them showed survival advantage over others 
except cetuximab.[3,7,9,11,12,13] The rate of response to the 
second-line chemotherapy was shown to be largely 
dependent on the therapy regimen given and on the 
treatment-free interval between initial and subsequent 
treatment.[16] Herbst et al.[15] reported the results of a 
cetuximab and cisplatin regimen and found that median 
OS was 4.3 months, and response rate was 13% in patients 
with documented PD or recurrence within 3 months of 
platinum-based therapy. Baselga et al.[16] showed a median 
OS of 5.0 months with a response rate of 11% in platinum-
refractory patients treated with cetuximab followed by 
platinum chemotherapy. Yokota et al.[17] reported the 
results of S1 monotherapy in SCCHN patients after the 
failure of platinum-based chemotherapy. In this study, 
the median PFS was 4.9 months and the median OS was 
13.2 months. In our study, median PFS was 5 months.
The primary aim of treatment in palliative setting in 
platinum-refractory or relapsed SCCHN is to provide 
symptomatic relief and secondary aim is to improve 
OS.[18] In LMICs like ours where the majority of the 
patients are from a lower socioeconomic background 
with poor nutrition, the use of therapies which are suitable 
to this population is warranted. Cetuximab is currently 
considered standard of care in platinum-refractory or 
relapsed patients with survival benefit and acceptable 
toxicity; however, its use is hampered in our country due 
to financial and logistical issues. Although taxanes have 
better response but at the cost of increased toxicity.[9] 
MTX, most economical and least toxic, appears to be 
the best alternative in this situation. Moreover, patients 
who are not willing for intravenous MTX and who are 
not able to come to hospital from remote areas of the 
country on weekly basis for intravenous MTX due to poor 
execution status or financial considerations, oral MTX can 
be considered an equally effective agent in these patients.
Conclusion
Oral MTX is a simple, cost-effective and well-tolerated 
regimen to be used on outpatient basis for palliation 
Table 2: Toxicity related to oral MTX
Grade 0 1 2 3 4
Mucositis 55 (76) 7 (9) 2 (3) 7 (10) 0
Anaemia 69 (97) 2 (3) ‑ ‑ ‑
Neutropenia 62 (87) 6 (9) 2 (2) 1 (1) ‑
Thrombocytopenia 68 (96) 3 (4) ‑ ‑ ‑
Febrile neutropenia ‑ ‑ ‑ ‑ ‑







CR: Complete response, PR: Partial response, SD: Stable disease, 
PD: Progressive disease
Figure 1: Progression-free survival
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in platinum-refractory or relapsed SCCHN in LMICs 
and debilitated patients. This treatment merits further 
evaluation in large-scale clinical trials.
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